Pacira BioSciences, Inc. Reports Net Loss of $19.5 Million in Q1 2023 Financial Statements
Revenue Reaches $160.3 Million for Pacira BioSciences, Inc. in Q1 2023 Unaudited Financials
By USInMinutes
Published - Aug 02, 2023, 01:47 PM ET
Last Updated - Aug 02, 2023, 01:47 PM EDT
Pacira BioSciences, Inc.(PCRX), a leading pharmaceutical company , has released its unaudited financial statements for the first quarter of 2023. The report shows a net loss of $19.5 million and a revenue of $160.3 million during the three-month period ended March 31, 2023.
Net Income/Loss
In the first quarter of 2023, Pacira BioSciences, Inc. recorded a net loss of $19.5 million. This comes amid a challenging operating environment for the pharmaceutical industry, influenced by various factors including research and development expenses, acquisition-related charges, and other operational costs.
